An interpretation of the 2-year follow-up results of Evolut Low Risk research
- VernacularTitle:Evolut Low Risk 研究两年随访结果解读
- Author:
Haoran YANG
1
;
Tianyuan XIONG
1
;
Mao CHEN
1
Author Information
1. Department of Cardiology, West China Hospital, Sichuan University, Chengdu, 610041, P.R.China
- Publication Type:Journal Article
- Keywords:
Aortic stenosis;
transcatheter aortic valve replacement (TAVR);
low risk
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2021;28(08):884-887
- CountryChina
- Language:Chinese
-
Abstract:
Transcatheter aortic valve replacement (TAVR) has become a well-established treatment for patients with severe aortic stenosis. At present, TAVR has already shown noninferiority and even superiority to surgical aortic valve replacement (SAVR) in patients deemed at high or intermediate risk for SAVR. However, the long-term follow-up results of the randomized controlled trials comparing the efficacy and safety between TAVR and SAVR are still lacking in those patients who are at low risk for SAVR. This paper gives an overview and reviews results of the Evolut Low Risk trial and interprets its implications for transcatheter therapy in aortic valve diseases.
